纳米药物在放射性肺损伤治疗中的研究进展  

Nanomedicine in the treatment of radiation-induced lung injury:research progress

作　　者：王航 杨彦勇[1] 高福[1] WANG Hang;YANG Yan-yong;GAO Fu(Department of Marine Radiation Medicine,Faculty of Naval Medicine,Naval Medical University(Second Military MedicalUniversity),Shanghai 200433,China)

机构地区：[1]海军军医大学(第二军医大学)海军医学系舰船辐射医学防护教研室,上海200433

出　　处：《海军军医大学学报》2022年第4期438-445,共8页Academic Journal of Naval Medical University

基　　金：军事医学创新工程专项(18CXZ008)。

摘　　要：放射性肺损伤是胸部恶性肿瘤放射治疗的常见并发症,目前仍缺乏有效治疗手段。近年来,纳米技术的发展为这一问题的解决带来了希望。纳米药物是指药物晶体或载体粒径为1~100 nm的颗粒,它可以利用本身物理特性或作为靶向载药系统改善药代动力学,增加药物在靶器官的分布,从而减轻放射性肺炎和肺纤维化症状,为放射性肺损伤的临床治疗提供新思路和新途径。本文综述了近年来纳米药物在放射性肺损伤治疗中的相关研究进展。Radiation-induced lung injury(RILI)is a common complication of radiotherapy for thoracic malignant tumors,and effective treatments are urgently required.Development of nanotechnology in recent years brings hope to the resolution of this problem.Nanomedicine is a drug crystal or carrier with size in the range of 1-100 nm,and it can improve pharmacokinetics and increase the biodistribution of therapeutic agents in the target organs with its own physical characteristics or targeted drug delivery system,so as to reduce the symptoms of radiation pneumonia and pulmonary fibrosis.These advantages have provided new perspectives and ways for clinical treatment of RILI.This article reviews the relevant progress in nanomedicine treatment of RILI in recent years.

关 键 词：纳米药物 放射性肺损伤 药物治疗 肺纤维化 靶向治疗 

分 类 号：R818.8[医药卫生—放射医学]